<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7139252/results/search/test_trace/results.xml">
  <result pre="a significant amount of the world's population will contract SARS-CoV-II" exact="infection" post="with the current spreading. While a specific treatment is"/>
  <result pre="contract SARS-CoV-II infection with the current spreading. While a specific" exact="treatment" post="is not yet coming soon, individual risk assessment and"/>
  <result pre="big challenges for the spreading of COVID-19 [20]. The close" exact="contact" post="to infected individuals, either asymptomatic or clinical COVID-19 cases,"/>
  <result pre="coughing, sneezing, and cooking. Social distancing helps to avoid close" exact="contact" post="with symptomatic and asymptomatic individuals [17]. Rapid identification, isolation,"/>
  <result pre="with symptomatic and asymptomatic individuals [17]. Rapid identification, isolation, and" exact="treatment" post="of the patients impact the spreading of SARS-CoV-II. The"/>
  <result pre="course and outcomes of COVID-19. As there is no specific" exact="treatment" post="for COVID-19, most of the case management is supportive"/>
  <result pre="global pandemic spreading, most of us may get the SARS-CoV-II" exact="infection" post="at a certain period. Therefore, individual actions that minimize"/>
  <result pre="at a certain period. Therefore, individual actions that minimize the" exact="infection" post="risk and modulate the severity of the clinical courses"/>
  <result pre="individual risk management strategies to reduce the risk of SARS-CoV-II" exact="infection" post="and moderate the severity of COVID-19. 2 Personal hygiene"/>
  <result pre="and moderate the severity of COVID-19. 2 Personal hygiene and" exact="social distancing" post="determine the individual risk of SARS-CoV-II infection While the"/>
  <result pre="hygiene and social distancing determine the individual risk of SARS-CoV-II" exact="infection" post="While the SARS-CoV-II remains viable in the aerosols for"/>
  <result pre="mediums is, therefore, the critical preventive measure, together with the" exact="social distancing" post="from the possible infected individual. Personal hygiene could reduce"/>
  <result pre="hands to the respiratory mucosal surfaces [25]. Social distancing prevents" exact="contact" post="with the aerosol droplets from infected individuals or asymptomatic"/>
  <result pre="inappropriate use and disposal of the mask may increase their" exact="infection" post="risks. Hence, there is a recommendation to use a"/>
  <result pre="ability to fight infection, diminished response to the vaccine, increased" exact="prevalence" post="of autoimmunity, and constitutive low-grade inflammation [34]. Conforming to"/>
  <result pre="to several age-related diseases and decreased immune functions [38,39]. This" exact="prevalence" post="is probably the consequence of the low appetite and"/>
  <result pre="to the virus [42]. While the immune responses to viral" exact="infection" post="determine the efficacy of a vaccine, the disrupted gut"/>
  <result pre="responses, that contribute to pneumonia development by the secondary bacterial" exact="infection" post="[44]. The healthy, diverse intestinal and respiratory tract microbiota"/>
  <result pre="infection. While the type I IFN signaling during acute viral" exact="infection" post="increase the pro-inflammatory responses, their signaling in the persistent"/>
  <result pre="infection increase the pro-inflammatory responses, their signaling in the persistent" exact="infection" post="modulates the counter-regulatory immune responses [47,48]. Some gut microbiomes"/>
  <result pre="[47,48]. Some gut microbiomes mediate the IFN responses to viral" exact="infection" post="through their metabolites, such as the Clostridium orbiscindens-derived desaminotyrosine"/>
  <result pre="of Lactobacillus also influence the IFN responses following the influenza" exact="infection" post="[50]. Host dietary pattern is the pivotal determinant of"/>
  <result pre="susceptible individuals for COVID-19 might alleviate their risk of severe" exact="infection" post="[54]. Despite the inconclusive pieces of evidence, oral probiotics"/>
  <result pre="vitamin D supplementation for the prevention of acute respiratory tract" exact="infection" post="[[62], [63], [64], [65]]. The effective supplementation needs to"/>
  <result pre="in the U.S. had vitamin D deficiency [69,70]. This high" exact="prevalence" post="probably contributes to the first outbreak COVID-19 during winter"/>
  <result pre="in healthy individuals for the prevention of acute viral respiratory" exact="infection" post="[76]. However, vitamin A deficient people are prone to"/>
  <result pre="in the early days [81,82]. The immune-modulating effects in respiratory" exact="infection" post="of vitamin C are also well-documented [[83], [84], [85],"/>
  <result pre="supporting evidence of vitamin C supplementation in the prevention and" exact="treatment" post="of acute respiratory diseases are inconclusive [[87], [88], [89],"/>
  <result pre="selenium has a critical role in the defense against viral" exact="infection" post="through its antioxidant, redox signaling, and redox homeostatic contributions"/>
  <result pre="state, the selenium supplementation is helpful for the prevention and" exact="treatment" post="of viral infections [[97], [98], [99], [100]]. Recently, it"/>
  <result pre="on the shortened of symptoms and duration of common cold" exact="infection" post="[[106], [107], [108]]. Zinc supplementation was also helpful against"/>
  <result pre="[108]]. Zinc supplementation was also helpful against hepatitis C virus" exact="infection" post="through the induction of metallothionein expressions [109,110]. Moreover, research"/>
  <result pre="COVID-19 pandemic, likely by improving the host's resistance against viral" exact="infection" post="[102]. However, these studies did not account for the"/>
  <result pre="Potential therapeutic options for COVID-19 There is yet no specific" exact="treatment" post="for COVID-19. Therefore, physicians are trying to fight the"/>
  <result pre="the chances of getting the SARS-CoV-II infection. Without the specific" exact="treatment" post="for COVID-19, we here explore some potential therapeutic options"/>
  <result pre="of the previously approved medications in these conditions for the" exact="treatment" post="of COVID-19. 5.2 The blockages of the virus entry"/>
  <result pre="these drugs are being tested in clinical trials in the" exact="treatment" post="of COVID-19. 5.3 The inhibitors of viral RNA synthesis"/>
  <result pre="studies suggested the effectiveness of remdesivir to selectively inhibit the" exact="infection" post="and pathology of MERS-CoV and SARS-CoV-II [125,126]. While the"/>
  <result pre="proofreading, thus renders its superior antiviral efficacy [127]. The experimental" exact="treatment" post="of intravenous remdesivir in the first COVID-19 patient in"/>
  <result pre="treatment, favipiravir is currently on the clinical trials for COVID-19" exact="treatment" post="by the National Infectious Diseases Scientific Science Research Center"/>
  <result pre="lopinavir-ritonavir combination is a fixed-dose medication for the prevention and" exact="treatment" post="of HIV infection [137]. The cytochrome P450 inhibitory effects"/>
  <result pre="a fixed-dose medication for the prevention and treatment of HIV" exact="infection" post="[137]. The cytochrome P450 inhibitory effects of ritonavir prolonged"/>
  <result pre="recent clinical trial reported no benefit of the lopinavir-ritonavir combination" exact="treatment" post="beyond the standard care in hospitalized adults with severe"/>
  <result pre="cytochrome P450 inhibitors, such as ritonavir or cobicistat, for the" exact="treatment" post="of HIV infection [143]. The in-vitro studies suggested the"/>
  <result pre="such as ritonavir or cobicistat, for the treatment of HIV" exact="infection" post="[143]. The in-vitro studies suggested the inhibitory action of"/>
  <result pre="individual. There is a long history of this passive antibody" exact="treatment" post="in various infective diseases beyond the era of antimicrobial"/>
  <result pre="There is no report of serious adverse effects of the" exact="treatment" post="up to now. The convalescent plasma from the patients"/>
  <result pre="plasma from the patients who have recovered from the viral" exact="infection" post="is thus another rational option for COVID-19 management [160,161]."/>
  <result pre="lot of world population will contract SARS-CoV infection. While specific" exact="treatment" post="is not yet coming soon, individual preventive and protective"/>
  <result pre="neededN. Engl. J. Med.38220201194119610.1056/NEJMp200212532074416 26HellewellJ.AbbottS.GimmaA.BosseN.I.JarvisC.I.RussellT.W.MundayJ.D.KucharskiA.J.EdmundsW.J.SunF.Feasibility of controlling COVID-19 outbreaks by" exact="isolation" post="of cases and contactsLancet Glob. Health82020e488e49610.1016/S2214-109X(20)30074-732119825 27OnderG.RezzaG.BrusaferroS.Case-fatality rate and"/>
  <result pre="by the intestinal microbiotaFront. Microbiol.62015108510.3389/fmicb.2015.0108526500629 46ZhouJ.WangY.ChangQ.MaP.HuY.CaoX.Type III interferons in viral" exact="infection" post="and antiviral immunityCell. Physiol. Biochem.51201817318530439714 47TeijaroJ.R.Type I interferons in"/>
  <result pre="acquired immune systemsCurr. Pharm. Des.24201871071710.2174/138161282466618011616341129345577 56EguchiK.FujitaniN.NakagawaH.MiyazakiT.Prevention of respiratory syncytial virus" exact="infection" post="with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055Sci. Rep.92019481210.1038/s41598-019-39602-730886158"/>
  <result pre="Pharmacol. Pharmacother.3201211812610.4103/0976-500X.9550622629085 69ElliottM.E.BinkleyN.C.CarnesM.ZimmermanD.R.PetersenK.KnappK.BehlkeJ.M.AhmannN.KieserM.A.Fracture risks for women in long-term care: high" exact="prevalence" post="of calcaneal osteoporosis and hypovitaminosis DPharmacotherapy23200370271010.1592/phco.23.6.702.3218212820811 70KennelK.A.DrakeM.T.HurleyD.L.Vitamin D deficiency"/>
  <result pre="72NonneckeB.McGillJ.RidpathJ.SaccoR.LippolisJ.ReinhardtT.Acute phase response elicited by experimental bovine diarrhea virus (BVDV)" exact="infection" post="is associated with decreased vitamin D and E status"/>
  <result pre="serum 25-hydroxyvitamin D level and risk of upper respiratory tract" exact="infection" post="in children and adolescentsClin Infect. Dis.57201339239710.1093/cid/cit28923677871 75WimalawansaS.J.Global epidemic of"/>
  <result pre="deficiency impairs the immune response to intranasal vaccination and RSV" exact="infection" post="in neonatal calvesSci. Rep.920191515710.1038/s41598-019-51684-x31641172 78PatelN.PenkertR.R.JonesB.G.SealyR.E.SurmanS.L.SunY.TangL.DeBeauchampJ.WebbA.RichardsonJ.HeineR.DallasR.H.RossA.C.WebbyR.HurwitzJ.L.Baseline serum vitamin A and"/>
  <result pre="and immunity: an essential interrelationArch. Biochem. Biophys.6112016586527021581 106ScienceM.JohnstoneJ.RothD.E.GuyattG.LoebM.Zinc for the" exact="treatment" post="of the common cold: a systematic review and meta-analysis"/>
  <result pre="upper respiratory tract infection?Evid. Based Pract.2320203739 108AwotiwonA.A.OduwoleO.SinhaA.OkwunduC.I.Zinc supplementation for the" exact="treatment" post="of measles in childrenCochrane Database Syst. Rev.62017CD01117710.1002/14651858.CD011177.pub328631310 109ReadS.A.ParnellG.BoothD.DouglasM.W.GeorgeJ.AhlenstielG.The antiviral"/>
  <result pre="trackNat. Biotechnol.202010.1038/d41587-020-00003-1(Epub ahead of print) 113KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E" exact="infection" post="in human epithelial lung cells (L132) by chloroquine: involvement"/>
  <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005(Epub ahead of print) 115GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.DupontH.HonoréS.ColsonP.ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and"/>
  <result pre="Crit. Care202010.1016/j.jcrc.2020.03.005(Epub ahead of print) 115GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.DupontH.HonoréS.ColsonP.ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
  <result pre="by a clinically proven protease inhibitorCell202010.1016/j.cell.2020.02.052(Epub ahead of print) 118MatsuyamaS.NaoN.ShiratoK.KawaseM.SaitoS.TakayamaI.NagataN.SekizukaT.KatohH.KatoF.SakataM.TaharaM.KutsunaS.OhmagariN.KurodaM.SuzukiT.KageyamaT.TakedaM.Enhanced" exact="isolation" post="of SARS-CoV-2 by TMPRSS2-expressing cellsProc. Natl. Acad. Sci. U.S.A.11720207001700310.1073/pnas.200258911732165541"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201610.1038/s41421-020-0156-032194981 127AmirianE.S.LevyJ.K.Current knowledge about the antivirals remdesivir"/>
  <result pre="RNA viral infectionsAntivir. Res.8220099510219428599 132De ClercqE.New nucleoside analogues for the" exact="treatment" post="of hemorrhagic fever virus infectionsChem. Asian J.1420193962396831389664 133WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and"/>
  <result pre="136ElfikyA.A.Anti-HCV, nucleotide inhibitors, repurposing against COVID-19Life Sci.202011747710.1016/j.lfs.2020.117477 137ChandwaniA.ShuterJ.Lopinavir/ritonavir in the" exact="treatment" post="of HIV-1 infection: a reviewTher. Clin. Risk Manag.420081023103310.2147/tcrm.s328519209283 138JiangF.DengL.ZhangL.CaiY.CheungC.W.XiaZ.Review"/>
  <result pre="J. Med.202010.1056/NEJMoa2001282(Epub ahead of print) 140ChuC.ChengV.HungI.WongM.ChanK.ChanK.KaoR.PoonL.WongC.GuanY.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 141KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Combination therapy"/>
  <result pre="and parasite drugsBioorg. Med. Chem.121020042517252110.1016/j.bmc.2004.03.03515110833 149YangY.IslamM.S.WangJ.LiY.ChenX.Traditional Chinese medicine in the" exact="treatment" post="of patients infected with 2019-new coronavirus (SARS-CoV-2): a review"/>
  <result pre="the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studiesViruses12202025410.3390/v12030254 167LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci. Trends142020697131996494 168National Institutes"/>
 </snippets>
</snippetsTree>
